TORONTO, June 9, 2026
SpinaFX Medical has achieved a major regulatory milestone after receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for Triojection®, its breakthrough minimally invasive, image-guided treatment designed for patients suffering from contained herniated lumbar discs. The IDE authorization enables the company to launch a pivotal U.S. clinical trial evaluating the safety, effectiveness, and economic impact of combining intradiscal ozone/oxygen injection therapy with conventional nerve root block treatment. The approval marks a significant advancement for SpinaFX as it seeks to address a substantial therapeutic gap in spinal care between conservative treatment options and invasive surgical interventions. With millions of patients worldwide affected by lumbar disc disorders annually, the upcoming trial could pave the way for a new minimally invasive treatment paradigm in spine medicine.
FDA IDE Approval Clears Path for Landmark U.S. Clinical Trial
Under the IDE authorization, SpinaFX plans to initiate a prospective, randomized, multicenter pivotal study enrolling approximately 300 patients across up to 30 specialty spine treatment centers throughout the United States. The trial will compare outcomes between patients receiving Triojection® intradiscal ozone/oxygen therapy combined with nerve root block and those receiving nerve root block treatment alone. The study is specifically designed for individuals with symptomatic contained lumbar disc herniation who have failed conservative therapies such as physical therapy, medications, and other non-surgical interventions.
Researchers aim to determine whether the addition of ozone-based intradiscal treatment can significantly improve pain reduction, functional recovery, and long-term patient outcomes. The trial will also generate important health economics data to assess whether the innovative approach can reduce healthcare costs associated with chronic lumbar disc disease while potentially delaying or avoiding surgery.
Innovative Image-Guided Therapy Targets Unmet Need in Spine Care
Advertisement
Lumbar disc herniation remains one of the most common causes of chronic back pain and disability worldwide, creating a substantial burden on patients and healthcare systems. Despite advances in treatment, many patients continue to face limited options once conservative care fails but before surgical intervention becomes necessary. Triojection® was developed to address this critical treatment gap through a minimally invasive, image-guided procedure that delivers a controlled ozone/oxygen mixture directly into the affected disc while simultaneously utilizing nerve root block therapy to alleviate symptoms. According to SpinaFX and its clinical advisors, intradiscal ozone therapy has been utilized in select international markets and has demonstrated encouraging outcomes in published studies outside the United States.
However, the FDA-authorized pivotal trial will provide the rigorous clinical evidence necessary to evaluate the therapy’s safety and effectiveness under U.S. regulatory standards. The study’s primary and secondary endpoints are expected to include clinically meaningful measures of pain relief, functional improvement, quality of life, and treatment durability over follow-up periods extending to 24 months.
Breakthrough Device Momentum Supports Future Regulatory Pathway
The IDE approval builds on the momentum generated by Triojection’s previously awarded FDA Breakthrough Device Designation, granted in August 2025. Together, these regulatory milestones position SpinaFX to accelerate the development of a novel treatment option for patients with disc-related pain and disability. Company leadership highlighted that the upcoming trial represents years of scientific and clinical development involving international experts in interventional neuroradiology and minimally invasive spine care. In addition to evaluating clinical outcomes, the study will support future discussions regarding reimbursement, healthcare utilization, and commercial adoption.
Successful trial results could ultimately support a future application for FDA marketing authorization and introduce a new category of image-guided intradiscal therapy into the U.S. healthcare system. As demand grows for less invasive alternatives to spinal surgery, the development of Triojection® underscores the broader trend toward precision-guided interventional therapies that aim to improve patient outcomes while reducing procedural complexity, recovery time, and overall healthcare expenditures.
Source: SpinaFX Medical press release
